ORCiD
Adam M. Kaye: 0000-0002-7224-3322
Document Type
Article
Publication Title
Neurology International
ISSN
2035-8385
Volume
13
Issue
3
DOI
10.3390/neurolint13030035
First Page
343
Last Page
358
Publication Date
9-1-2021
Abstract
Purpose of Review: This is a comprehensive review of the literature regarding the use of paliperidone in the treatment of schizophrenia and schizoaffective disorder. It covers the background and presentation of schizophrenia and schizoaffective disorder, as well as the mechanism of action and drug information for paliperidone. It covers the existing evidence of the use of paliperidone for the treatment of schizophrenia and schizoaffective disorder. Recent Findings: Schizophrenia and schizoaffective disorder lead to significant cognitive impairment. It is thought that dopamine dysreg-ulation is the culprit for the positive symptoms of schizophrenia and schizoaffective disorder. Similar to other second-generation antipsychotics, paliperidone has affinity for dopamine D2 and serotonin 5-HT2A receptors. Paliperidone was granted approval in the United States in 2006 to be used in the treatment of schizophrenia and in 2009 for schizoaffective disorder. Summary: Schizophrenia and schizoaffective disorder have a large impact on cognitive impairment, positive symptoms and negative symptoms. Patients with either of these mental illnesses suffer from impairments in everyday life. Paliperidone has been shown to reduce symptoms of schizophrenia and schizoaffective disorder.
Recommended Citation
Minwalla, H. D.,
Wrzesinski, P.,
Desforges, A.,
Caskey, J.,
Wagner, B.,
Ingraffia, P.,
Patterson, J. C.,
Edinoff, A. N.,
Kaye, A. M.,
Kaye, A. D.,
Viswanath, O.,
&
Urits, I.
(2021).
Paliperidone to treat psychotic disorders.
Neurology International, 13(3), 343–358.
DOI: 10.3390/neurolint13030035
https://scholarlycommons.pacific.edu/phs-facarticles/582
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
